Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers Health was launching a cut-price version of Novo's blockbuster Wegovy weight loss pill.
Novo Nordisk CEO: Hims' $49 compounded Wegovy pill a 'waste' of money
